Best in Biotech 8 Jan 2025
Ten drugs to watch in 2025: will these therapies become blockbusters?
Here are some of the drugs that are predicted to become blockbusters in the next few years, according to Clarivate’s latest report.
Cancer
- Latest Posts
Best in Biotech 30 Dec 2024
Six biotech companies leading the way in India
Discover six of the top biotech companies in India, which is currently brimming with biotechs and a young, skilled workforce.
In Depth 25 Dec 2024
When biotech makes Christmas miracles a reality
Explore how biotech breakthroughs in 2024 have changed lives, bringing real Christmas miracles to patients and offering hope for the future.
In Depth 17 Dec 2024
Ovarian cancer: BioNTech, Curelab, OvarianVax and more bring vaccines to the clinic
A number of ovarian cancer vaccines are being evaluated including the world’s first cancer prevention vaccine, which recently received funding.
Best in Biotech 16 Dec 2024
10 biotech companies to watch in 2025
As 2025 is expected to be an exciting year for the biopharma industry, discover ten biotech companies to keep an eye on in 2025.
News and Trends 12 Dec 2024
Top biotech deals of November 2024
November has seen a variety of biotech deals take place to advance therapies across different stages in development.
ADVERTISEMENT
ADVERTISEMENT
In Depth 11 Dec 2024
Targeting sugar molecules: Can glycobiology lead to a new era for cancer immunotherapy?
Find out more about the emerging field of glycobiology, which could potentially lead to a new type of cancer immunotherapy.
In Depth 2 Dec 2024
The rise of cancer vaccines: A new era in immunotherapy
Delve into the expanding and diverse field of cancer vaccines with various approaches exploiting the immune system to fight tumors.
Best in Biotech 26 Nov 2024
Seven miRNA-focused companies pioneering new therapies in 2024
Delve into the field of miRNA with seven companies with miRNA-focused candidates in the pipeline in 2024, from oncology to neurodegeneration.
Harnessing antibody-drug conjugates (ADCs) in oncology: Pathways to clinical success
Discover how ADCs are advancing oncology, the regulatory challenges they face, and the promise they hold for the future of cancer treatment.
Best in Biotech 19 Nov 2024
Six bispecific antibody companies you should know about
Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.
In Depth 18 Nov 2024
What is Abcam’s founder, Jonathan Milner, up to?
Since Abcam was acquired in December 2023, its founder, Jonathan Milner has been very active. Delve into his investment strategy.
ADVERTISEMENT
